US Stock MarketDetailed Quotes

SUPN Supernus Pharmaceuticals

Watchlist
  • 32.280
  • +0.120+0.37%
Trading Mar 18 15:38 ET
1.80BMarket Cap24.45P/E (TTM)

Supernus Pharmaceuticals Key Stats

Supernus Pharmaceuticals Q4 2024 Earnings Date

Currency:USDFeb 25, 2025

Estimate
(YoY)
Actual
(YoY)
Vs Estimate
(% Chg)
Revenue
155.25M
174.16M
+18.91M
Beat Est.
-5.52%
+5.99%
+12.18%
EPS
0
0.27
+0.27
Beat Est.
-100.00%
+1450.57%
--
Buy

Feb 28, 2025

Supernus Pharmaceuticals Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 5 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 154.219M--
--2025/Q1-- / 146.736M--
Feb 25, 20252024/Q4174.159M / 155.252M--
Nov 4, 20242024/Q3175.689M / 157.298M--
Aug 6, 20242024/Q2168.325M / 148.852M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 154.219M--
--2025/Q1-- / 146.736M--
Feb 25, 20252024/Q4174.159M / 155.252M--
Nov 4, 20242024/Q3175.689M / 157.298M--
Aug 6, 20242024/Q2168.325M / 148.852M--

Unlock Free Earnings Estimates

Supernus Pharmaceuticals Earnings Reports

Read more

Trending Stocks

Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Unlock Now
Discussing
Big Tech’s earnings season in full swing! Nvidia is the only one left
On Thursday, $Amazon (AMZN.US)$ stock fell after the firm reported Q4 adjusted earnings of $1.86/share, vs estimates of $1.50/share, on reve Show More